Because inflammation-driven ovarian cancer was found to enhance CXCL1-3 expression[10], - targeting CXCR2, a specific receptor for CXCL1-3, may be a therapeutic strategy as suggested by others[47]. Here, CXCL13 is linked to ovarian carcinoma.